News & Events zu Zimmer Biomet Holdings, Inc (ZBH)ZBHZimmer Biomet Holdings, Inc

Zimmer Biomet Reports Q2 Revenue of $2.18B, Raises Full-Year Guidance

Reports Q2 revenue $2.18B, consensus $2.14B. "We delivered strong second quarter results with solid top- and bottom-line performance and continued progress on our key growth drivers and commercial transformation," said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. "With a strong first half, healthy underlying markets, go-to-market changes progressing as planned and continued momentum from our innovation cycle, we are raising our revenue and adjusted EPS guidance for the year. Importantly, we continue to advance our strategic priorities and remain confident our efforts will strengthen our business, build the boldest leader in MedTech, and better position Zimmer Biomet to deliver consistent, durable growth over the long term."

Raises FY26 Revenue Outlook to 3.9%-4.9%

Consensus $8.47. Raises FY26 revenue view to up 3.9%-4.9% from 2.5%-4.5%.

Pacira Divests iovera degrees to Zimmer Biomet for Up to $140M

Pacira (PCRX) announced the divestiture of iovera degrees to Zimmer Biomet (ZBH). The iovera degrees system is a FDA-cleared, drug-free medical device that relieves pain via cryoneurolysis-a process whereby focused cold therapy is applied to a targeted nerve, temporarily interrupting its ability to transmit pain signals. Under the terms of the transaction, Pacira will receive up to $140M with an upfront payment of $70M and potential future revenue-based milestone payments totaling up to an additional $70M during the period up to and through December 31, 2031. The parties will collaborate on advancing the spasticity program with an opportunity for Pacira to receive incremental compensation assuming successful completion of the registrational study and subsequent regulatory approval. Zimmer Biomet will obtain all of Pacira's rights, titles and interests for the development, manufacture and commercialization of iovera degrees. Upon closing, the company intends to use the upfront net proceeds to strengthen its balance sheet including the pay down of its senior secured revolving credit facility. To support a smooth transition of iovera degrees into Zimmer Biomet, the parties intend to enter into a customary transition services agreement in connection with the closing. The closing of the transaction is subject to the satisfaction or waiver of customary closing conditions. The transaction is expected to close in the third quarter of 2026.